AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06433921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
Trial: NCT06186531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.
Trial: NCT05513573
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg, D1，Q3W
Trial: NCT05513573
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles
Trial: NCT05708508
Drug: ROVALCYTE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immuno-guided strategy arm
Trial: NCT05179577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT06368960
Drug: BM201 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BM201 injection：Dose escalation：24mg to 240mg
Trial: NCT06161220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching the carbidopa capsules
Trial: NCT06253650
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of: T-DXd at the dose of 6.4 mg/kg intravenous every 3 weeks plus capecitabine 1000 mg/sqm BID orally on days 1-14 every 3 weeks or 5-fluorouracil 600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks as per Investigator's choice
Trial: NCT04984200
Drug: Mydriatic Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered mydriatic medication to dilate their pupils.
Trial: NCT05470283
Drug: OBX-115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT05470283
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT04778579
Drug: ARI-0001 cells
RxNorm normalized name: OVIS ARIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
Trial: NCT05206370
Drug: Cytisinicline
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Trial: NCT05206370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated oral tablets containing matched placebo
Trial: NCT06564987
Drug: 4% Articaine with 1:200,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inferior Alveolar Nerve Block with 4% articaine
Trial: NCT06564987
Drug: 2% lidocaine with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inferior Alveolar Nerve Block with 2% lidocaine
Trial: NCT05406401
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT05406401
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05406401
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV or oral administration (per local guidelines)
Trial: NCT06505395
Drug: SYHX2008 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will accept SYHX2008 injection by subcutaneous administration every cycle.
Trial: NCT06505395
Drug: Sandostatin LAR@
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.
Trial: NCT06082843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Avenciguat (BI 685509)
Trial: NCT06564935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drops (identical to heptaminol drops, prepared by the hospital pharmacy) will be administered 1.5 to 2 hours before spinal anesthesia.
Trial: NCT06283966
Drug: BGF MDI 320/14.4/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension
Trial: NCT06283966
Drug: GFF MDI 14.4/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium and formoterol fumarate pressurized inhalation suspension
Trial: NCT06493526
Drug: Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycophenolate mofetil dose will be optimized to an AUC12 of 60 h.mg/L, thereafter the calcineurin inhibitor will be withdrawn.
Trial: NCT05360784
Drug: Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
Trial: NCT05660642
Drug: BPL-003
RxNorm normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#BPLEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
Trial: NCT06414031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT05014919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT04708847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection
Trial: NCT04846998
Drug: BR9003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group B:~Once-daily oral administration of one BR9003 2mg tablet in the fasting state.~Treatment group C:~Once-daily oral administration of one BR9003 2mg tablet after a meal(high-fat meal) 30 minutes before the scheduled time of administration and finishing it.
Trial: NCT04846998
Drug: BR9003A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group A:~Twice-daily oral administration of one BR9003A 1mg tablet in the fasting state
Trial: NCT06549231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one course of intravenous placebo of rituximab consisting of an infusion of 500 mL of saline (0.9% sodium chloride) infusion will be given at day 1, day 15 and week 24;
Trial: NCT05781451
Drug: LY3361237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
Trial: NCT04724837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo as per the arms they are randomized to.
Trial: NCT05011383
Drug: High dose testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose testosterone is administered subcutaneously once monthly until progression or toxicity
Trial: NCT05660109
Drug: TPM502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
Trial: NCT05410223
Drug: Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Trial: NCT05410223
Drug: IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Trial: NCT05410223
Drug: Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.
Trial: NCT05410223
Drug: IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Trial: NCT05645380
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2, IV
Trial: NCT05645380
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, IV
Trial: NCT05938946
Drug: L608 Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
Trial: NCT05938946
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
Trial: NCT05677347
Drug: GSK3923868
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3923868 will be administered
Trial: NCT05677347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered
Trial: NCT04908046
Drug: HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile.~Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly.
Trial: NCT05724069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
Trial: NCT04905212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
Trial: NCT05294172
Drug: KL-A167
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.
Trial: NCT05294172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-6 cycles for combined therapy.Placebo maintenance.
Trial: NCT05240560
Drug: BP1.3656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H3 receptor antagonist/inverse agonist
Trial: NCT06493084
Drug: LAE102 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous drip or subcutaneous injection
Trial: NCT05321602
Drug: LY03010 156 mg treatment group, deltoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Trial: NCT05321602
Drug: LY03010 156 mg treatment group, gluteal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Trial: NCT05321602
Drug: LY03010 351 mg treatment group, deltoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Trial: NCT05321602
Drug: LY03010 351 mg treatment group, gluteal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Trial: NCT04855435
Drug: MBS8(1V270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
Trial: NCT06456060
Drug: Alvogyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvogyl soaked in a sterile gauze will be applied to cover the socket.
Trial: NCT05501899
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients \< 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)
Trial: NCT05887336
Drug: Non preserved ocular lubricants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Hyaluronic acid (HyloGel)~* Hyaluronic acid and Ectoin (Hylo Dual Intense)~* Hyaluronic acid and Trehalos (Theloz Duo)
Trial: NCT05708859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume matched Subcutaneous Solution
Trial: NCT06569524
Drug: TQA2225/AP025 or TQA2225/AP025 Placebo 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the efficacy and safety of TQA2225/AP025 (25mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
Trial: NCT06569524
Drug: TQA2225/AP025 or TQA2225/AP025 Placebo 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the efficacy and safety of TQA2225/AP025 (50mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
Trial: NCT05095922
Drug: Heart-Protecting Musk Pill
RxNorm normalized name: Tri-Heart Plus Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
Trial: NCT05095922
Drug: Calcium Dobesilate Capsules
RxNorm normalized name: calcium dobesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
Trial: NCT06316570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Placebo of Ticagrelor (180mg) + Placebo of Aspirin (100mg), one dose;~Days 2-7: Placebo of Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day).
Trial: NCT05064618
Drug: Am80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medicine taken internally
Trial: NCT04840186
Drug: 2nd line chemotherapy
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist
Trial: NCT06545617
Drug: BAT8006 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.
Trial: NCT06674148
Drug: Qifangfeixian granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group was treated with Qifangfixian granules
Trial: NCT04837196
Drug: ASP7517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV)
Trial: NCT06273254
Drug: Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex
Trial: NCT05385978
Drug: APHD-012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal jejunal-release dextrose beads (Aphaia technology, AT)
Trial: NCT05385978
Drug: APHD-012P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal jejunal-release placebo beads
Trial: NCT05212740
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment will initiate with a dose of 0.5 mg/kg/day prednisolone for two weeks and the dose will halve in the next two weeks.
Trial: NCT06146062
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections one week apart
Trial: NCT05422066
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
Trial: NCT05422066
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
Trial: NCT04755647
Drug: Nitric Oxide-Releasing Solution
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active antimicrobial
Trial: NCT04755647
Drug: Saline solution, hypotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06639191
Drug: [177Lu]Lu-AKIR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient cohorts of a minimum of three and a maximum of 12 evaluable participants will be opened according to the decision tree defined in the protocol and will be consecutively completed. When one cohort has been completed and fully evaluated, the next cohort will be opened after all participants in the previous cohort have received at least one dose of the IMP without dose-limiting toxicities during a follow-up period of at least six weeks.~The \[177Lu\]Lu-AKIR001 protein mass dose and activity are predefined for each cohort, and could be adjusted according to the results of previous cohort(s) to ensure the safety of participants. The initial design of the trial encompasses five cohorts to escalate both \[177Lu\]Lu-AKIR001 pmd, from 50 mg to 100 mg, and activity, from 0.75 to 3.0 GBq.
Trial: NCT06641388
Drug: Ebronucimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebronucimab subcutaneous injection
Trial: NCT06636578
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: will not receive any regional anesthesia and only will receive I.V. fentanyl 1μg/kg/hr.
Trial: NCT05525520
Drug: EP547
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT05525520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT06570746
Drug: Sedative
RxNorm normalized name: Sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation is applied before the procedure
Trial: NCT06569459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy and immunotherapy in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
Trial: NCT05860244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Syrup for 6 months
Trial: NCT06563869
Drug: PEG-rhG-GSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycolylated recombinant human granulocyte stimulating factor （6mg）will be given 24 hours after the end of chemotherapy.
Trial: NCT05583955
Drug: NOE-105
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained
Trial: NCT05583955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose levels of matching Placebo will be given
Trial: NCT05840913
Drug: Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge
RxNorm normalized name: articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic injection for intra- operative pain control